Loading…

Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease

Autonomic nervous system (ANS) involvement is frequently found in Parkinson's disease (PD), but its causal relationship to the disease itself and its medication is unclear. We evaluated the effects of PD medications on cardiovascular ANS functions. Heart rate (HR) responses to normal and deep b...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurology 2000-11, Vol.247 (11), p.868-874
Main Authors: HAAPANIEMI, Tarja H, KALLIO, Mika A, KORPELAINEN, Juha T, SUOMINEN, Kalervo, TOLONEN, Uolevi, SOTANIEMI, Kyösti A, MYLLYLÄ, Vilho V
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c376t-3514fa6faad2f53c91490e86368c19bcf4b9fd42dc042bad4599517eb536914d3
cites
container_end_page 874
container_issue 11
container_start_page 868
container_title Journal of neurology
container_volume 247
creator HAAPANIEMI, Tarja H
KALLIO, Mika A
KORPELAINEN, Juha T
SUOMINEN, Kalervo
TOLONEN, Uolevi
SOTANIEMI, Kyösti A
MYLLYLÄ, Vilho V
description Autonomic nervous system (ANS) involvement is frequently found in Parkinson's disease (PD), but its causal relationship to the disease itself and its medication is unclear. We evaluated the effects of PD medications on cardiovascular ANS functions. Heart rate (HR) responses to normal and deep breathing, the Valsalva manoeuvre and tilting, and blood pressure (BP) responses to tilting and isometric work were measured prospectively in 60 untreated PD patients randomised to receive either levodopa (n = 20), bromocriptine (n = 20) or selegiline (n = 20) as their initial treatment. The results were compared with those of 28 healthy controls. The responses were recorded at baseline, after 6 months on medication and following a 6-week washout period. At baseline HR responses to normal breathing, deep breathing and tilting were already lower and the fall in the systolic BP immediately and at 5 min after tilting was more pronounced in the PD patients than in the controls. Six months' levodopa treatment diminished the systolic BP fall after tilting when compared to baseline, whereas bromocriptine and selegiline increased the fall in systolic BP after tilting and selegiline diminished the BP responses to isometric work. The BP responses returned to the baseline values during the washout period. The drugs induced no change in the HR responses. Thus PD itself causes autonomic dysfunction leading to abnormalities in HR and BP regulation and the PD medications seem to modify ANS responses further. Bromocriptine and selegiline, in contrast to levodopa, increase the orthostatic BP fall and suppress the BP response to isometric exercise reflecting mainly impairment of the sympathetic regulation.
doi_str_mv 10.1007/s004150070075
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_754874769</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72526795</sourcerecordid><originalsourceid>FETCH-LOGICAL-c376t-3514fa6faad2f53c91490e86368c19bcf4b9fd42dc042bad4599517eb536914d3</originalsourceid><addsrcrecordid>eNp90c9r2zAUB3AxWpa023HXYjpoLvUmWT9sHUtou0KgPXTHYWT9KMpsydWLA_nvp5Cwsh4GAknow-M9fRH6QvA3gnH9HTBmhOdTXvwDmhNGq5IwLk_QHFOGS045m6EzgDXGuMkPH9GMEMIJq_Ac_VrZbTRxVNdFl-IQdfLjxgdbqGAKsL198f3-OkTj3a7QKhkftwr01KtUJAtjDGCh8KF4Uum3DxDDAgrjwSqwn9CpUz3Yz8f9HP28u31e_ihXj_cPy5tVqWktNiXNzTglnFKmcpxqSZjEthFUNJrITjvWSWdYZTRmVadMHkJyUtuOU5Gtoedocag7pvg6Wdi0gwdt-14FGydoa86amtVCZnn1f1nxStSSZ3j5Dq7jlEKeouV1Q5kQZF-tPCCdIkCyrh2TH1TatQS3-3jaf-LJ_uJYdOoGa970MY8Mvh5B_mLVu6SC9vDXNTlRJukf50mWpw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>578346619</pqid></control><display><type>article</type><title>Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease</title><source>Springer Nature</source><creator>HAAPANIEMI, Tarja H ; KALLIO, Mika A ; KORPELAINEN, Juha T ; SUOMINEN, Kalervo ; TOLONEN, Uolevi ; SOTANIEMI, Kyösti A ; MYLLYLÄ, Vilho V</creator><creatorcontrib>HAAPANIEMI, Tarja H ; KALLIO, Mika A ; KORPELAINEN, Juha T ; SUOMINEN, Kalervo ; TOLONEN, Uolevi ; SOTANIEMI, Kyösti A ; MYLLYLÄ, Vilho V</creatorcontrib><description>Autonomic nervous system (ANS) involvement is frequently found in Parkinson's disease (PD), but its causal relationship to the disease itself and its medication is unclear. We evaluated the effects of PD medications on cardiovascular ANS functions. Heart rate (HR) responses to normal and deep breathing, the Valsalva manoeuvre and tilting, and blood pressure (BP) responses to tilting and isometric work were measured prospectively in 60 untreated PD patients randomised to receive either levodopa (n = 20), bromocriptine (n = 20) or selegiline (n = 20) as their initial treatment. The results were compared with those of 28 healthy controls. The responses were recorded at baseline, after 6 months on medication and following a 6-week washout period. At baseline HR responses to normal breathing, deep breathing and tilting were already lower and the fall in the systolic BP immediately and at 5 min after tilting was more pronounced in the PD patients than in the controls. Six months' levodopa treatment diminished the systolic BP fall after tilting when compared to baseline, whereas bromocriptine and selegiline increased the fall in systolic BP after tilting and selegiline diminished the BP responses to isometric work. The BP responses returned to the baseline values during the washout period. The drugs induced no change in the HR responses. Thus PD itself causes autonomic dysfunction leading to abnormalities in HR and BP regulation and the PD medications seem to modify ANS responses further. Bromocriptine and selegiline, in contrast to levodopa, increase the orthostatic BP fall and suppress the BP response to isometric exercise reflecting mainly impairment of the sympathetic regulation.</description><identifier>ISSN: 0340-5354</identifier><identifier>EISSN: 1432-1459</identifier><identifier>DOI: 10.1007/s004150070075</identifier><identifier>PMID: 11151420</identifier><identifier>CODEN: JNRYA9</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Aged ; Biological and medical sciences ; Blood Pressure - drug effects ; Blood Pressure - physiology ; Bromocriptine - therapeutic use ; Cardiovascular System - drug effects ; Cardiovascular System - physiopathology ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Female ; Humans ; Levodopa - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Neurology ; Parkinson Disease - drug therapy ; Parkinson Disease - physiopathology ; Parkinson's disease ; Selegiline - therapeutic use</subject><ispartof>Journal of neurology, 2000-11, Vol.247 (11), p.868-874</ispartof><rights>2001 INIST-CNRS</rights><rights>Steinkopff Verlag 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c376t-3514fa6faad2f53c91490e86368c19bcf4b9fd42dc042bad4599517eb536914d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=803449$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11151420$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HAAPANIEMI, Tarja H</creatorcontrib><creatorcontrib>KALLIO, Mika A</creatorcontrib><creatorcontrib>KORPELAINEN, Juha T</creatorcontrib><creatorcontrib>SUOMINEN, Kalervo</creatorcontrib><creatorcontrib>TOLONEN, Uolevi</creatorcontrib><creatorcontrib>SOTANIEMI, Kyösti A</creatorcontrib><creatorcontrib>MYLLYLÄ, Vilho V</creatorcontrib><title>Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease</title><title>Journal of neurology</title><addtitle>J Neurol</addtitle><description>Autonomic nervous system (ANS) involvement is frequently found in Parkinson's disease (PD), but its causal relationship to the disease itself and its medication is unclear. We evaluated the effects of PD medications on cardiovascular ANS functions. Heart rate (HR) responses to normal and deep breathing, the Valsalva manoeuvre and tilting, and blood pressure (BP) responses to tilting and isometric work were measured prospectively in 60 untreated PD patients randomised to receive either levodopa (n = 20), bromocriptine (n = 20) or selegiline (n = 20) as their initial treatment. The results were compared with those of 28 healthy controls. The responses were recorded at baseline, after 6 months on medication and following a 6-week washout period. At baseline HR responses to normal breathing, deep breathing and tilting were already lower and the fall in the systolic BP immediately and at 5 min after tilting was more pronounced in the PD patients than in the controls. Six months' levodopa treatment diminished the systolic BP fall after tilting when compared to baseline, whereas bromocriptine and selegiline increased the fall in systolic BP after tilting and selegiline diminished the BP responses to isometric work. The BP responses returned to the baseline values during the washout period. The drugs induced no change in the HR responses. Thus PD itself causes autonomic dysfunction leading to abnormalities in HR and BP regulation and the PD medications seem to modify ANS responses further. Bromocriptine and selegiline, in contrast to levodopa, increase the orthostatic BP fall and suppress the BP response to isometric exercise reflecting mainly impairment of the sympathetic regulation.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Blood Pressure - physiology</subject><subject>Bromocriptine - therapeutic use</subject><subject>Cardiovascular System - drug effects</subject><subject>Cardiovascular System - physiopathology</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Female</subject><subject>Humans</subject><subject>Levodopa - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson Disease - physiopathology</subject><subject>Parkinson's disease</subject><subject>Selegiline - therapeutic use</subject><issn>0340-5354</issn><issn>1432-1459</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNp90c9r2zAUB3AxWpa023HXYjpoLvUmWT9sHUtou0KgPXTHYWT9KMpsydWLA_nvp5Cwsh4GAknow-M9fRH6QvA3gnH9HTBmhOdTXvwDmhNGq5IwLk_QHFOGS045m6EzgDXGuMkPH9GMEMIJq_Ac_VrZbTRxVNdFl-IQdfLjxgdbqGAKsL198f3-OkTj3a7QKhkftwr01KtUJAtjDGCh8KF4Uum3DxDDAgrjwSqwn9CpUz3Yz8f9HP28u31e_ihXj_cPy5tVqWktNiXNzTglnFKmcpxqSZjEthFUNJrITjvWSWdYZTRmVadMHkJyUtuOU5Gtoedocag7pvg6Wdi0gwdt-14FGydoa86amtVCZnn1f1nxStSSZ3j5Dq7jlEKeouV1Q5kQZF-tPCCdIkCyrh2TH1TatQS3-3jaf-LJ_uJYdOoGa970MY8Mvh5B_mLVu6SC9vDXNTlRJukf50mWpw</recordid><startdate>20001101</startdate><enddate>20001101</enddate><creator>HAAPANIEMI, Tarja H</creator><creator>KALLIO, Mika A</creator><creator>KORPELAINEN, Juha T</creator><creator>SUOMINEN, Kalervo</creator><creator>TOLONEN, Uolevi</creator><creator>SOTANIEMI, Kyösti A</creator><creator>MYLLYLÄ, Vilho V</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20001101</creationdate><title>Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease</title><author>HAAPANIEMI, Tarja H ; KALLIO, Mika A ; KORPELAINEN, Juha T ; SUOMINEN, Kalervo ; TOLONEN, Uolevi ; SOTANIEMI, Kyösti A ; MYLLYLÄ, Vilho V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c376t-3514fa6faad2f53c91490e86368c19bcf4b9fd42dc042bad4599517eb536914d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Blood Pressure - physiology</topic><topic>Bromocriptine - therapeutic use</topic><topic>Cardiovascular System - drug effects</topic><topic>Cardiovascular System - physiopathology</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Female</topic><topic>Humans</topic><topic>Levodopa - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson Disease - physiopathology</topic><topic>Parkinson's disease</topic><topic>Selegiline - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HAAPANIEMI, Tarja H</creatorcontrib><creatorcontrib>KALLIO, Mika A</creatorcontrib><creatorcontrib>KORPELAINEN, Juha T</creatorcontrib><creatorcontrib>SUOMINEN, Kalervo</creatorcontrib><creatorcontrib>TOLONEN, Uolevi</creatorcontrib><creatorcontrib>SOTANIEMI, Kyösti A</creatorcontrib><creatorcontrib>MYLLYLÄ, Vilho V</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HAAPANIEMI, Tarja H</au><au>KALLIO, Mika A</au><au>KORPELAINEN, Juha T</au><au>SUOMINEN, Kalervo</au><au>TOLONEN, Uolevi</au><au>SOTANIEMI, Kyösti A</au><au>MYLLYLÄ, Vilho V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease</atitle><jtitle>Journal of neurology</jtitle><addtitle>J Neurol</addtitle><date>2000-11-01</date><risdate>2000</risdate><volume>247</volume><issue>11</issue><spage>868</spage><epage>874</epage><pages>868-874</pages><issn>0340-5354</issn><eissn>1432-1459</eissn><coden>JNRYA9</coden><abstract>Autonomic nervous system (ANS) involvement is frequently found in Parkinson's disease (PD), but its causal relationship to the disease itself and its medication is unclear. We evaluated the effects of PD medications on cardiovascular ANS functions. Heart rate (HR) responses to normal and deep breathing, the Valsalva manoeuvre and tilting, and blood pressure (BP) responses to tilting and isometric work were measured prospectively in 60 untreated PD patients randomised to receive either levodopa (n = 20), bromocriptine (n = 20) or selegiline (n = 20) as their initial treatment. The results were compared with those of 28 healthy controls. The responses were recorded at baseline, after 6 months on medication and following a 6-week washout period. At baseline HR responses to normal breathing, deep breathing and tilting were already lower and the fall in the systolic BP immediately and at 5 min after tilting was more pronounced in the PD patients than in the controls. Six months' levodopa treatment diminished the systolic BP fall after tilting when compared to baseline, whereas bromocriptine and selegiline increased the fall in systolic BP after tilting and selegiline diminished the BP responses to isometric work. The BP responses returned to the baseline values during the washout period. The drugs induced no change in the HR responses. Thus PD itself causes autonomic dysfunction leading to abnormalities in HR and BP regulation and the PD medications seem to modify ANS responses further. Bromocriptine and selegiline, in contrast to levodopa, increase the orthostatic BP fall and suppress the BP response to isometric exercise reflecting mainly impairment of the sympathetic regulation.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>11151420</pmid><doi>10.1007/s004150070075</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0340-5354
ispartof Journal of neurology, 2000-11, Vol.247 (11), p.868-874
issn 0340-5354
1432-1459
language eng
recordid cdi_proquest_miscellaneous_754874769
source Springer Nature
subjects Aged
Biological and medical sciences
Blood Pressure - drug effects
Blood Pressure - physiology
Bromocriptine - therapeutic use
Cardiovascular System - drug effects
Cardiovascular System - physiopathology
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Female
Humans
Levodopa - therapeutic use
Male
Medical sciences
Middle Aged
Neurology
Parkinson Disease - drug therapy
Parkinson Disease - physiopathology
Parkinson's disease
Selegiline - therapeutic use
title Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T11%3A25%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Levodopa,%20bromocriptine%20and%20selegiline%20modify%20cardiovascular%20responses%20in%20Parkinson's%20disease&rft.jtitle=Journal%20of%20neurology&rft.au=HAAPANIEMI,%20Tarja%20H&rft.date=2000-11-01&rft.volume=247&rft.issue=11&rft.spage=868&rft.epage=874&rft.pages=868-874&rft.issn=0340-5354&rft.eissn=1432-1459&rft.coden=JNRYA9&rft_id=info:doi/10.1007/s004150070075&rft_dat=%3Cproquest_cross%3E72526795%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c376t-3514fa6faad2f53c91490e86368c19bcf4b9fd42dc042bad4599517eb536914d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=578346619&rft_id=info:pmid/11151420&rfr_iscdi=true